Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)

Acute Interstitial Nephritis Clinical Trial

Official title:
Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)

Status Withdrawn

Clinical Trial Summary

The investigators goal is to evaluate the role of XOLAIR® in treatment of Acute Tubulointerstitial Nephritis (AIN) with the goal of shortening the duration and dose of prednisone for treatment of drug-induced AIN. Currently there is no good treatment for drug-induced AIN. Prednisone is the standard treatment but is associated with many side-effects when used long-term and at high doses.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01893658
Study type	Interventional
Source	Mayo Clinic
Contact
Status	Withdrawn
Phase	Phase 2
Start date	June 1, 2018
Completion date	September 28, 2018

View Details

See also
	Status	Clinical Trial	Phase
	Enrolling by invitation	`NCT04343417` - Biorepository to Support Research in Kidney Diseases
	Not yet recruiting	`NCT05233241` - Identification of the Causative Drug in Drug-induced Acute Interstitial Nephritis	N/A